Policy Engagement
SWHR provided open input to the Institute for Clinical and Economic Review (ICER) on contextual considerations surrounding Alzheimer’s disease (AD) and its treatment from a women’s health perspective.
ICER recently initiated a new topic review of AD to assess the comparative clinical effectiveness and value of aducanumab, a new AD treatment slated for review by the Food and Drug Administration in early 2021.
Last year, SWHR conceived a set of principles to help ensure value frameworks and assessments account for patient population diversity and have the infrastructure and analytic capability to evaluate data that matters to women. Grounded by these principles, SWHR encouraged ICER to: